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In the Fractional Flow Reserve versus Angiography for
Multivessel Evaluation 2 (FAME 2) study, 888 patients
with stable coronary artery disease were randomised either
to fractional flow reserve (FFR)-guided percutaneous cor-
onary intervention (PCI) plus optimal medical therapy or
optimal medical therapy alone [1]. Before randomization,
FFR was measured in all angiographically visible stenoses
and patients who had at least one stenosis in a major cor-
onary artery with a FFR of 0.80 or less were randomised.
Patients who did not fulfil criteria were followed in a
separate registry. This inclusion algorithm resulted in an
optimal selection of patients for PCI as judged by current
standards. Recruitment was halted prematurely because of
a significant between-group difference in the percentage of
patients who had a primary endpoint event. The primary
endpoint was a composite of death, myocardial infarction
(MI) or urgent revascularization. The difference in primary
endpoint events at 1 year into the study (12.7 % in the
medical-therapy group vs. 4.3 % in the PCI group) was
driven by a higher number of urgent revascularizations in
the medical-therapy group (11.1 vs. 1.6 %). There was also
a trend towards fewer hard events (death or myocardial
infarction) in the PCI group (3.4 vs. 3.9 % or 15 vs. 17
events, respectively) [1]. In a so-called ‘‘landmark’’ ana-
lysis from 8 days to 1 year (which excluded the excess
number of peri-interventional endpoints in the PCI group
occurring between days 1 and 7), this small difference was
transformed into a hazard ratio of 0.42 in favour of PCI
with a p value of 0.053.
The design of this important study included two aspects
which resulted in a disadvantage for the medical-therapy
group. First, patients had to be informed about the fact that
they had a significant stenosis which was left untreated
because they had been randomised to the medical-therapy
group. It is easy to imagine what kind of effect such
knowledge would have if some even mild form of chest
pain recurred. The patient would necessarily interpret this
as a signal of impending doom and present to the hospital.
There he would be treated as a patient with unstable angina
and—knowing that he harboured a high-grade stenosis—be
immediately brought to the catheterization laboratory. The
treating doctor would not hesitate and dilate the stenosis.
This would generate an endpoint ‘‘urgent revascularisa-
tion’’ in the medical-therapy group. Unfortunately, it would
be difficult to design the study in a way that such an effect
could be avoided. Only if the medically treated group
would undergo a sham procedure [2]—similar to the design
of the simplicity-3 trial [3]—would it have been possible to
achieve comparable and unbiased conditions. Is the
occurrence of chest pain, be it provoked by exercise or
occurring at rest, an emergency which needs to be treated
by PCI immediately? Resting chest pain occurs frequently
in patients with stable angina and is often caused by cor-
onary spasm [4]. One very good treatment for spasm is the
addition of a calcium antagonist of the existing medication.
However, we are not told that this was ever tried in the
medical-therapy patients. Thus, the study design inevitably
puts patients in the medical-therapy group at a higher risk
for the occurrence of events. This first bias involved in the
study design makes it necessary to focus on the smaller
group of patients who presented with an unstable coronary
syndrome and objective evidence of ischemia such a new
troponin elevation or ST-segment changes not present in
the previous ECG. At 1 year such an ACS constellation
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was present in 23 (5.2 %) vs. 4 (0.9 %) patients in the
medical-therapy and the PCI groups indicating that there
was a real difference in truly indicated urgent revascular-
isations. These patients, however, represent just half of the
total number of urgent revascularizations [49 (11.1 %) vs.
7 (1.6 %)] in the medical-therapy and PCI groups,
respectively.
The second disadvantage for the medically treated group
was due to the fact that the larger number of revascular-
izations in the medical-therapy group in patients without
objective evidence of ischemia probably also triggered
additional hard events in the medical-therapy group. PCI
not infrequently results in periprocedural elevations of
troponin. Such an event, however, was likely counted as an
additional hard event (non-ST-elevation myocardial
infarction) occurring in the group with medical therapy.
The authors do not comment on how such events were
counted and on the number of events occurring this way.
Recently, FAME 2 again produced headlines when the
2-year follow-up results were simultaneously presented at
the ESC Congress in Barcelona and online in the New
England Journal of Medicine [5]. At 2 years, the ‘‘land-
mark’’ analysis of hard events (death or MI) occurring after
day 7 following randomisation and PCI up to 2 years
produced a significantly higher number of events in the
medical-therapy group than in the PCI group. The excite-
ment was heightened by the fact that this was the first trial
of PCI vs. medical therapy ever which showed a reduction
of hard events in the interventional group. Less exciting
was that the significant difference in the number of primary
outcomes in favour of the PCI group already demonstrated
after 1 year was unchanged at 2 years (8.1 vs. 19.5 % in
the PCI vs. the medical-therapy group). As after 1 year,
this difference was exclusively driven by a lower rate of
urgent revascularizations in the PCI group (4.0 vs. 16.3 %).
And again, only a subgroup of patients had their revascu-
larizations triggered by objective markers of ischemia such
as troponin rises or ischemic changes on electrocardiog-
raphy. However, as after 1 year such revascularisations
were significantly less frequent in the PCI group than in the
medical-therapy group (3.4 vs. 7 %, p = 0.01). Interest-
ingly, this ‘‘hard’’ between-group difference had become
smaller at 2 years than after 1 year (3.6 vs. 4.3 %). There
was no significant between-group difference in the total
rates of death and MI (PCI group: 29 patients experiencing
death or MI (6.5 %) vs medical group: death or MI in 36
patients (8.2 %, p = 0.37). The absolute number of events
was 6 deaths in the PCI group and 8 deaths in the medical-
therapy group. However, in each group, only 3 of the
deaths were cardiac in origin. The number of MIs at the
end of year 2 was 26 in the PCI group and 30 in the
medical-therapy group (Fig. 1). This would include
patients who had some troponin rise after urgent
revascularization disfavouring the medical-therapy group
(see above). Thus, one can also conclude that the trial
clearly shows an absence of benefit in terms of hard events
of well-conducted state-of-the-art PCI in stable angina
patients. Interestingly, no graph (neither in the paper nor in
the appendix) shows the total number of hard events over
time including those occurring between days 0 and 7.
Instead, attention was focused on the significantly lower
rate in the PCI group when the first 7 days were excluded
(4.6 vs. 8.0 %, p = 0.04). This skewed vision of the results
was promoted by the fact that the lack of a significant
difference in hard endpoints over the entire time from
randomisation up to 2 years (which is only clinically
meaningful) was placed in a table in the appendix whereas
the ‘‘landmark’’ analysis was mentioned in the summary of
the trial. Heartwire commented that ‘‘PCI is superior to
medical therapy for the reduction of hard clinical endpoints
in patients with stable coronary artery disease’’. Such a
disinformation policy will most likely create inaccurate
brain engrams in readers who necessarily do not have the
time to go into much detail when trying to keep abreast
with current studies.
How can it be explained that despite the absence of an
increasing difference between groups from year 1 to year 2
statistics of the ‘‘landmark’’ analysis came up with a sig-
nificant difference in favour of the PCI group at year 2
which was not found after year 1? This effect was probably
caused by the slightly larger number of total events in both
groups whereas the absolute difference in both groups
remained even decreased slightly. If one looks closer at the
numbers of ‘‘urgent’’ revascularisations one sees that the
difference in revascularizations triggered by objective
evidence narrowed from 19 events at 1 year to 16 events at
the end of the second year of follow-up indicating that
during year two of follow-up both groups fared equally
well. However, this is not mentioned anywhere in the
paper.
Thus, a number of critical questions have to be asked.
First, is it clinically important whether a p value changes
from 0.053 to 0.04? Second, how many of the MIs in the
two groups of FAME 2 were clinically relevant Q-wave
MIs and how many were just mild troponin rises? Third,
how many of these troponins rise occurred in the context of
more or less urgent revascularization? Finally, can the
slightly higher rate of deaths of all causes be used as an
argument against medical therapy when the number of
cardiac deaths was identical?
An argument in favour of immediate PCI in patients
with stable angina who are FFR positive put forward by the
authors was that more than 40 % of patients treated by
medical therapy had crossed over by 2 years of follow-up,
i.e. had undergone any revascularization (Fig. 2). How-
ever, another way of looking at the data (Fig. 3) is that
284 Clin Res Cardiol (2015) 104:283–287
123
almost 110 % of the patients in the PCI group had under-
gone any revascularization over the period of the 2 years
whereas only slightly more than 40 % of those originally
assigned to medical therapy alone had needed PCI. This
means that more than 60 % of patients in the medical-
therapy group had not needed PCI. If one puts the total
Fig. 1 Kaplan–Meier Curve for the Death and Myocardial Infarction
Landmark Analysis (adapted from [5]). The cumulative incidences of
death or myocardial infarction in the two study groups, stratified on
the basis of a landmark point at 7 days after randomization (vertical
dashed line) are shown. The hazard ratios shown for PCI versus
medical therapy were calculated separately for events that occurred
within 7 days and those that occurred between 8 days and the end of
follow-up at 2 years. Data for the first 7 days are not included in the
period after 7 days. The insets show the data for days 0 to 7 on an
expanded y axis. Hazard ratios below 1.00 denote a lower incidence
of the end point in the PCI group than in the medical-therapy group.
The absolute number of hard events is shown in box, the centre of the
figure. p value denotes the significant difference calculated in favour
of PCI in the 2-year landmark analysis. The green bars indicated the
absolute difference between the two curves at 1 year. It is evident that
at 2 years no further separation of the two curves occurred
Fig. 2 Urgent and non-urgent
revascularisations in FAME 2 at
2 years. After 2 years, [40 %
of patients treated by MT had
crossed over, i.e. had undergone
any revascularisation
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number of revascularizations into one graph with the
number of hard events one sees the discrepancy between
difference in the numbers of revascularizations and the
difference in the numbers of heart events. Considering that
many of the hard events were probably mild troponin
elevations following resting angina without objective evi-
dence of ischemia, the achievement of PCI appears even
less impressive.
Thus, the main messages from the 2-year follow-up of
the milestone FAME 2 study are the following:
First Immediate PCI in a cohort of patients in whom
two-thirds have proximal or mid LAD stenosis and who
have stable angina, does not result in a worse outcome
than medical therapy alone. However, this statement is
probably only true if PCI is FFR guided. Second The
benefit in terms of reductions of myocardial infarction and
death in the PCI group is very small and non-significant
(1.7 %, p = 0.37). The difference does only seem to be
statistically significant if one ignores the higher rate of
MIs and death in the PCI group within the first 7 days
after the intervention. However, this ‘‘landmark’’ type of
analysis is clinically irrelevant. Third Repeated attacks of
angina are of course worrying for the patient and reducing
the number of patients with such symptoms is a valuable
goal. However, revascularization of all the patients ful-
filling the entire criteria for FAME 2 will result in
overtreating many of these patients at unnecessary cost to
society. Fourth: FAME 2 clearly demonstrates that no
harm will be done if revascularization is postponed until
the patient has reoccurrence of symptoms with or without
some troponin rise.
The interventional community should not be enticed by
the irrelevant yet highly publicised result of the ‘‘land-
mark’’ analysis to forget current guideline recommenda-
tions for the treatment of patients with stable coronary
disease [6, 7]. The guidelines request objective evidence of
ischemia in the perfusion bed of the coronary artery for
which PCI is intended. Such proof of regional ischemia can
also be provided by cardiac imaging. However, at inclusion
into FAME 2 only slightly more than 20 % of patients had
undergone any ischemia test. The situation in clinical
practice may be even worse: many patients still undergo
PCI without proof of regional ischemia and without use of
FFR. The good outcome in patients with negative FFR
which were followed-up in a separate registry in FAME 2
indicates that proof of ischemia is indeed mandatory before
performing PCI in stable CAD patients.
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Fig. 3 Modification of Fig. 2
with all points on the blue curve
increased by 100 %
revascularisation performed in
that group. It becomes clear that
the PCI procedure could be
avoided in a large portion of
patients in the medically treated
group (about 60 %) without a
worse outcome in terms of hard
events
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